Estrogens and Benign Prostatic Hyperplasia: Rationale for Therapy with Aromatase Inhibitors
- 1 January 1991
- journal article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 23 (3) , 201-203
- https://doi.org/10.3109/07853899109148048
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Histological localization of estrogen receptors in normal and diseased human prostates by immunocytochemistryThe Prostate, 1990
- Controversies About Indications for Transurethral Resection of the ProstateJournal of Urology, 1989
- Etiology and disease process of benign prostatic hyperplasiaThe Prostate, 1989
- Selective inhibition of androstenedione‐induced prostate growth in intact beagle dogs by a combined treatment with the antiandrogen cyproterone acetate and the aromatase inhibitor 1‐methyl‐androsta‐1,4‐diene‐3,17‐dione (1‐methyl‐ADD)The Prostate, 1989
- Nuclei of stroma: Site of highest estrogen concentration in human benign prostatic hyperplasiaThe Prostate, 1982
- Stroma of human benign prostatic hyperplasia: preferential tissue for androgen metabolism and oestrogen bindingActa Endocrinologica, 1981
- Examination of the distribution of oestrogen receptor between the stromal and epithelial compartments of the canine prostateThe Prostate, 1980
- Anatomy of the prostate: An historical survey of divergent viewsThe Prostate, 1980
- The induction of prostatic hypertrophy in the dog with androstanediol.Journal of Clinical Investigation, 1976
- Die Entstehung der sogenannten ProtatahypertrophieVirchows Archiv, 1925